APGE Apogee Therapeutics
Price Chart
Executive Summary
Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, including up to $800 million in synthetic royalty funding and up to $500 million in senior corporate debt. Combined with its existing $1.3 billion cash, this positions Apogee to fund Phase 3 development and potential commercialization of zumilokibart without future equity financing. The deal is the largest royalty financing for a pre-Phase 3 program and was announced alongside APEX Phase 2 Part B data.
Key Financial Metrics
Actionable Insight
This financing removes near-term dilution risk and extends runway through commercialization. The Phase 2 data readout and Blackstone's endorsement are strong catalysts. Monitor the 8:00 a.m. ET webcast for APEX Part B efficacy/safety details and any updates on Phase 3 timeline.
Key Facts
- Up to $1.3 billion in non-dilutive capital from Blackstone Life Sciences, including up to $800 million synthetic royalty and up to $500 million senior corporate debt.
- First $400 million preapproval funding: $100M at signing, $100M upon Phase 3 enrollment completion, $200M upon positive Phase 3 data.
- Up to $400 million additional funding available upon FDA approval, $150M at Apogee's option.
- Royalty term of 15 years on worldwide annual sales of zumilokibart, with no royalties on global annual sales exceeding $8 billion.
- Company removing its cash runway end date guidance, citing self-sustainable financial profile through commercialization without future equity financing.
- Apogee currently has $1.3 billion in total cash.
- Goldman Sachs served as exclusive financial advisor to Apogee.
Financial Impact
Up to $1.3 billion in non-dilutive capital, with $100 million received at signing. Combined with existing $1.3 billion cash, total pro-forma liquidity exceeds $2.6 billion.
Risk Factors
- Phase 3 data may not meet expectations, jeopardizing milestone payments and approval.
- Royalty obligation reduces future revenue per dollar of sales.
- Senior debt (up to $500M) adds leverage if drawn.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301723 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
13d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
8-K
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 27, 2026
13d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 26, 2026
14d ago
|
Press Release
| $77.75 $78.71 | ▲ +1.23% | ▲ +0.03% | $83.01 (+6.77%) |
|
May 16, 2026
25d ago
|
Insider Cluster
| $78.75 $82.81 | ▲ +5.16% | ▲ +3.54% | $83.01 (+5.41%) |
|
May 13, 2026
27d ago
|
144
| $83.94 $81.39 | ▼ −3.04% | ▼ −2.90% | $83.01 (−1.11%) |
|
May 11, 2026
29d ago
|
8-K
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $83.01 (−1.88%) |
|
May 11, 2026
29d ago
|
Press Release
| $84.60 $78.75 | ▼ −6.91% | ▼ −6.83% | $83.01 (−1.88%) |
|
May 1, 2026
5w ago
|
Insider Cluster
| $80.75 $83.03 | ▲ +2.82% | ▲ +0.48% | $83.01 (+2.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access